Browse drugs

…t, double-blind, placebo-controlled study evaluating daily oral AISA-021 for moderate to severe RP. In Part A, 27 patients from two site…

…epth longitudinal immunological evaluation of PLWH switching to long-acting injectable cabotegravir plus rilpivirine (LA-CAB/RPV).Material and Methods Three time p…

…ructured clinical care pathway designed to optimize delivery of LA-ART through organizational redesign. We evaluated early implementat…

…ith TGFbeta, the PIM inhibitor AZD1208 and/or the ATM inhibitor KU60019 for 20 h. Glycolysis and mitochondrial respiration were assesse…

…a more severe phenotype, including more severe skin disease. In rTOPO mice, SiO2 inhalation also had systemic effects with exacerbate…

…tra cellular matrix proteins and alleviate lung fibrosis in the bleomycin model.…

…ing HOCl or PBS (control) for 42 days (D42); ii) mice receiving HOCl or PBS for 63 days (D63) and; iii) mice receiving HOCl or PBS f…

… mean disease duration was 7.2±6.2 years. All patients received prednisolone at mean dose of 10.6±4.3 mg/day. 9% of patients received cyclop…

…, poly- ATA+ cathrin endocytosis pathway blockage pretreatment [chlorpromazine) and poly-ATA + caveoin endocytosis pathway blockage pretreatme…

… findings suggest that NVC, in combination with biomarkers like KL-6, can serve as valuable tools for risk stratification and monito…

…endothelin receptor antagonists (ERA), and 33% on dual therapy (ERA + phosphodiesterase inhibitors). Only one case of pulmonary ede…

…through CMR. Based on recent evidence, combination therapy with rituximab (RTX, 2 x 1000 mg with a two-week gap and a repeat dose after s…